Pfizer vaccine effective for 90% of those undergoing cancer treatment

Embargoed until: Publicly released: 2021-05-29 01:00

International

Angiola Harry

Researchers studied the blood of 102 adult cancer patients who had received two doses of the Pfizer vaccine and were actively undergoing treatment. Nine in ten of the patients had COVID-19 antibodies after the second dose, indicating the vaccine had been effective for those patients. Comparing the results with 78 vaccinated people not undergoing cancer treatment, the researchers found everyone in that group had COVID-19 antibodies.

Media release

From: JAMA

What the study did

Rates of antispike antibody response to a messenger RNA SARS-CoV-2 vaccine in Israeli patients with cancer who are undergoing systemic treatment compared with healthy controls were evaluated in this study.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA Oncology

Research:Paper

Organisation/s: Rabin Medical Center, Beilinson Hospital, Israel

Funder: Conflict of Interest Disclosures: Dr Yust-Katz reported grants from MSD and personal fees from Honorarium Teva, Novartis, Novocure, and AstraZeneca outside the submitted work. Dr Zer reported personal fees from Roche, AstraZeneca, MSD, and Takeda as well as grants from BMS outside the submitted work. Dr Zaks reported personal fees from Moderna outside the submitted work. Dr S. M. Stemmer received research grants (to the institution) from CANFITE, AstraZeneca, Bioline RX, BMS, Halozyme, Clovis Oncology, CTG Pharma, Exelexis, Geicam, Halozyme, Incyte, Lilly, Moderna, Teva pharmaceuticals, and Roche and own stocks and options in CTG Pharma, DocBoxMD, Tyrnovo, VYPE, Cytora, and Canfite. No other disclosures were reported.

Media Contact/s

Contact details are only visible to registered journalists.